Login / Signup

Complement Activation Products in Patients with Chronic Schizophrenia.

Krzysztof RudkowskiKatarzyna WaszczukErnest TyburskiKatarzyna Rek-OwodzińPiotr PlichtaPiotr PodwalskiMaksymilian BieleckiMonika MakAnna MichalczykArkadiusz TelesińskiKatarzyna SielatyckaMarta BudkowskaKarolina ŁuczkowskaBarbara DolegowskaMariusz Z RatajczakJerzy SamochowiecJolanta Kucharska-MazurLeszek Sagan
Published in: Journal of clinical medicine (2023)
Evidence suggests a role of the immune system in the pathogenesis of a number of mental conditions, including schizophrenia (SCH). In terms of physiology, aside from its crucial protective function, the complement cascade (CC) is a critical element of the regeneration processes, including neurogenesis. Few studies have attempted to define the function of the CC components in SCH. To shed more light on this topic, we compared the levels of complement activation products (CAP) (C3a, C5a and C5b-9) in the peripheral blood of 62 patients with chronic SCH and disease duration of ≥ 10 years with 25 healthy controls matched for age, sex, BMI and smoking status. Concentrations of all the investigated CAP were elevated in SCH patients. However, after controlling for potential confounding factors, significant correlations were observed between SCH and C3a (M = 724.98 ng/mL) and C5a (M = 6.06 ng/mL) levels. In addition, multivariate logistic regression showed that C3a and C5b-9 were significant predictors of SCH. There were no significant correlations between any CAP and SCH symptom severity or general psychopathology in SCH patients. However, two significant links emerged between C3a and C5b-9 and global functioning. Increased levels of both complement activation products in the patient group as compared to healthy controls raise questions concerning the role of the CC in the etiology of SCH and further demonstrate dysregulation of the immune system in SCH patients.
Keyphrases